このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Imugene 過去の業績

過去基準チェック /06

Imugeneの収益は年間平均-47.1%の割合で減少していますが、 Biotechs業界の収益は年間増加しています。収益は年間12.4% 30.2%割合で増加しています。

主要情報

-54.1%

収益成長率

-43.5%

EPS成長率

Biotechs 業界の成長	9.6%
収益成長率	20.8%
株主資本利益率	-126.6%
ネット・マージン	-3,011.7%
前回の決算情報	30 Jun 2024

Recent updates

Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Nov 11

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Aug 22

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Feb 28

A Look At Imugene's (ASX:IMU) CEO Remuneration

Feb 17

Announcing: Imugene (ASX:IMU) Stock Soared An Exciting 733% In The Last Five Years

Dec 24

収支内訳

Imugene の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

ASX:IMU 収益、費用、利益 ( )AUD Millions
日付	収益	収益	G+A経費	研究開発費
30 Jun 24	5	-150	60	87
31 Mar 24	10	-119	53	75
31 Dec 23	15	-89	46	63
30 Sep 23	13	-64	33	47
30 Jun 23	12	-38	20	31
31 Mar 23	12	-39	19	33
31 Dec 22	12	-40	17	35
30 Sep 22	13	-39	15	36
30 Jun 22	13	-38	14	37
31 Mar 22	11	-33	14	29
31 Dec 21	8	-27	14	22
30 Sep 21	8	-23	12	19
30 Jun 21	7	-18	10	15
31 Mar 21	7	-15	8	14
31 Dec 20	6	-12	6	12
30 Sep 20	5	-11	6	11
30 Jun 20	4	-11	6	9
31 Mar 20	5	-10	6	9
31 Dec 19	5	-9	6	9
30 Sep 19	5	-8	5	8
30 Jun 19	4	-8	5	8
31 Mar 19	3	-7	4	6
31 Dec 18	3	-6	4	5
30 Sep 18	2	-5	3	4
30 Jun 18	2	-4	3	3
31 Mar 18	1	-3	2	3
31 Dec 17	1	-3	1	3
30 Sep 17	1	-3	1	2
30 Jun 17	1	-3	1	2
31 Mar 17	1	-3	1	3
31 Dec 16	2	-3	2	3
30 Sep 16	2	-3	2	3
30 Jun 16	2	-3	2	3
31 Mar 16	1	-3	1	2
31 Dec 15	1	-2	1	2
30 Sep 15	1	-2	1	2
30 Jun 15	1	-2	1	2
31 Mar 15	1	-2	1	1
31 Dec 14	1	-2	1	1
30 Sep 14	1	-2	1	1
30 Jun 14	1	-2	1	0
31 Mar 14	0	-2	1	0
31 Dec 13	0	-2	1	0
30 Sep 13	0	-2	1	0

質の高い収益: IMUは現在利益が出ていません。

利益率の向上: IMUは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: IMUは利益が出ておらず、過去 5 年間で損失は年間47.1%の割合で増加しています。

成長の加速: IMUの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: IMUは利益が出ていないため、過去 1 年間の収益成長をBiotechs業界 ( -2.6% ) と比較することは困難です。

株主資本利益率

高いROE: IMUは現在利益が出ていないため、自己資本利益率 ( -45.8% ) はマイナスです。

Imugene 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Recent updates

Imugene Limited Announces Promising Results from its Phase 1b Clinical Trial with Azer-Cel

New minor risk - Financial position

Is Imugene (ASX:IMU) In A Good Position To Invest In Growth?

Forecast to breakeven in 2027

Executive Chairman recently sold AU$1.1m worth of stock

Imugene Limited Announce Enrolment Opened for Its Expansion Study in Bile Tract Cancer (Cholangiocarcinoma) Patients

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Imugene Limited Announces Phase 1 onCARlytics Solid Tumour Trial Advances to Combination Arm Treatment

Price target decreased by 8.2% to AU$0.34

New minor risk - Share price stability

Imugene Limited, Annual General Meeting, Nov 30, 2023

New minor risk - Profitability

No longer forecast to breakeven

Price target decreased by 14% to AU$0.42

Less than half of directors are independent

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Price target decreased by 14% to AU$0.42

Imugene Limited Appoints Paul Woodard as Chief Medical Officer

Imugene Limited Appoints John Byon as Senior Vice President of Clinical Development

Imugene Limited Appoints Dr Bradley Glover as Chief Operating Officer

Imugene Appoints Dr Weitzman Interim Chief Medical Officer

Forecast to breakeven in 2026

Imugene Limited Announces Board Changes

We're Not Very Worried About Imugene's (ASX:IMU) Cash Burn Rate

Price target decreased by 9.8% to AU$0.46

Imugene Limited Announces VAXINIA Trial Advances to Combination Cohort 1 & Monotherapy Cohort 3

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Imugene Limited Receives Vaxinia Ethics Approval in Australia

Imugene Limited Presents New and First CHECKvacc Data At the 2022 San Antonio Breast Cancer Symposium

Imugene Limited Announces First Patient Dosed in VAXINIA Intravenous Cohort 2

Insufficient new directors

Price target decreased to AU$0.52

Here's Why Shareholders May Consider Paying Imugene Limited's (ASX:IMU) CEO A Little More

Imugene Dose Escalates in Phase I Clinical Trial of New Oncolytic Virus VAXINIA

Independent Non-Executive Director exercised options to buy AU$3.2m worth of stock.

Imugene Limited Announces That First Patient Dosed in VAXINIA Intratumoral Cohort 2

Imugene Limited, Annual General Meeting, Nov 17, 2022

Price target decreased to AU$0.51

Imugene Limited Announces First patient IV dosed in VAXINIA Phase 1 clinical trial

Imugene Limited Announces That Australian Government's Office of the Gene Technology Regulator (Ogtr) Has Granted Imugene the Dir Licence Required to Expand Its Vaxinia Phase 1 Clinical Trial Within Australia

Consensus forecasts updated

Price target decreased to AU$0.52

Imugene Limited Doses First Patient in nextHERIZON Phase 2 Trial

Imugene Appoints Jakob Dupont as Non- Executive Director

Imugene Dose Escalates in Phase I Clinical Trial of New Oncolytic Virus VAXINIA

Imugene (ASX:IMU) Is In A Good Position To Deliver On Growth Plans

Imugene Limited Announces First Cohort 3 Patient Dosed in Clinical Trial of CHECKvacc

Imugene Limited Appoints Mike Tonroe as Chief Financial Officer, Effective from September 2022

Imugene Limited Announces Appointment of Dr. Sharon Yavrom as Executive Director, Clinical Scientist

Imugene Limited Announces Final HER-Vaxx Phase 2 Trial Overall Survival Results

Consensus forecasts updated

Independent Non-Executive Director exercised options to buy AU$1.5m worth of stock.

Imugene Limited Announces Board Changes

City of Hope and Imugene Announce First Patient Dosed in Phase 1 Trial to Test Cancer-Killing Oncolytic Virus Against Solid Tumors

Imugene Limited Receives Ethics Approval to Start Phase 2 nextHERIZON Clinical Trial of Cancer Immunotherapy HER-VAXX

Imugene Limited Announces First Cohort 2 Patient Dosed in Clinical Trial of CHECKvacc

Consensus forecasts updated

Here's Why We're Not Too Worried About Imugene's (ASX:IMU) Cash Burn Situation

Imugene Limited Announces Appointment of Steven Cha as Chief Medical Officer and Member of the Executive Management Team

Imugene Limited Receives Notice of Grant from the European Patent Office for Patent Application Number

Imugene Completes Phase 1a Monotherapy Dose Escalation of Immunotherapy PD1-Vaxx

Executive Chairman recently sold AU$37m worth of stock

Imugene Limited Receives US Food and Drug Administration (FDA) Investigational New Drug (IND) Approval to Initiate A Phase I Clinical Trial of its Oncolytic Virotherapy Candidate, Vaxinia (CF33-hNIS, HOV2)

Imugene Limited Provides Update on Clinical Trial of Oncolytic Virotherapy CHECKvacc

Insider recently sold AU$1.4m worth of stock

Imugene Limited Provides Phase 1 Clinical Trial Update of Its Immunotherapy Pd1-Vaxx

Imugene Presents HER-Vaxx Update at ESMO World GI Congress

Imugene Limited Announces FDA IND Approval of New Oncolytic Virotherapy Checkvacc Virotherapy Checkvacc

CEO, MD & Executive Director exercised options and sold AU$1.6m worth of stock

Independent Non-Executive Director recently sold AU$1.2m worth of stock

Imugene Limited has completed a Follow-on Equity Offering in the amount of AUD 0.324115 million.

Revenue and earnings in line with expectations

A Look At Imugene's (ASX:IMU) CEO Remuneration

Imugene Limited Commences Cohort 2 Dosing in Phase 1 PD1-Vaxx Trial

Imugene Limited Dose Escalates in Phase I Clinical Trial of New Checkpoint Immunotherapy PD1-VAXX

過去基準チェック /06